Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04803058
PHASE2

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)

Sponsor: ITB-Med LLC

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients

Official title: A Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-Myeloablative Conditioning, Including Fludarabine and Cyclophosphamide, for Tolerance Induction in Living Donor Renal Transplantation

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

18

Start Date

2022-12-14

Completion Date

2030-03

Last Updated

2026-02-06

Healthy Volunteers

No

Interventions

BIOLOGICAL

TCD601

Investigational Product

Locations (3)

Massachusetts General Hospital

Boston, Massachusetts, United States

Mayo Clinic

Rochester, Minnesota, United States

Samsung Medical University

Seoul, South Korea